C4 Therapeutics, Inc.

NASDAQ:CCCC

Biotechnology

Healthcare
$2.48 +2.06%

+$0.08 today

Market cap
$325.01M
Beta
2.93
P/E (TTM)
-4.9
EPS (TTM)
-$0.82
52W Low $1.36High $4.60

Volume 2.75M

Average 2.76M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$98.69M

FY 2025 · Annual

Investing Cash Flow

-$8.60M

FY 2025 · Annual

Financing Cash Flow

$126.40M

FY 2025 · Annual

+178.8% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(83.89M)(128.18M)(132.49M)(105.32M)(104.99M)
Depreciation & Amortization1.49M1.68M1.88M1.82M1.96M
Deferred Income Tax1.88M0000
Stock-Based Compensation21.51M30.02M27.24M29.66M19.1M
Change in Working Capital(30.09M)(16.78M)(6.94M)7.65M(29.28M)
Accounts Receivables(1.23M)4.24M(10.33M)8.7M701K
Inventory(2.63M)0000
Accounts Payables(1.18M)(3.33M)273K(119K)(468K)
Other Working Capital(25.05M)(17.69M)3.12M(930K)(29.52M)
Other Non-Cash Items2.13M7.32M3.48M1.03M14.52M
Operating Cash Flow(86.97M)(105.94M)(106.84M)(65.16M)(98.69M)
Capital Expenditures(1.28M)(5.5M)(1.71M)(180K)(607K)
Acquisitions (Net)188.06M(63.92M)000
Purchases of Investments(537.74M)(219.53M)(129.9M)(284.32M)(227.07M)
Sales of Investments349.68M283.45M289.96M233.23M219.08M
Other Investing Activities(188.06M)63.92M000
Investing Cash Flow(189.34M)58.42M158.35M(51.27M)(8.6M)
Debt Repayment00(12.5M)00
Common Stock Issued169.47M777K57.67M44.37M126.32M
Common Stock Repurchased00(110K)(194K)(193K)
Dividends Paid00000
Other Financing Activities1.94M370K426K1.16M274K
Financing Cash Flow171.4M1.15M45.49M45.34M126.4M
Effect of Forex Changes00000
Net Change in Cash(104.9M)(46.37M)97M(71.09M)19.1M
Free Cash Flow(88.24M)(111.44M)(108.55M)(65.34M)(99.3M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$105.0M
+ D&A$2.0M
+ Stock-Based Comp$19.1M
+ Deferred Tax$0
- Working Capital-$29.3M
+ Other Non-Cash$14.5M
= Operating Cash Flow-$98.7M
- Capex-$607.0K
= Free Cash Flow-$99.3M

Analysis

FY2025 free cash flow is -$99.3M. FCF conversion is 94.6% of net income. Operating cash flow was -$98.7M, with capex of -$607.0K. The largest bridge item is Working Capital at -$29.3M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
4Statement of changes in beneficial ownershipNov 13, 2026
8-KCurrent reportNov 5, 2026
10-QQuarterly reportNov 5, 2026
4Statement of changes in beneficial ownershipOct 2, 2026
4Statement of changes in beneficial ownershipOct 2, 2026

Does CCCC generate free cash flow?

C4 Therapeutics, Inc. (CCCC) generated -$99.30M of free cash flow in fiscal 2025.

How much operating cash flow does CCCC produce?

Operating cash flow was -$98.69M, before capital expenditures of $607,000.00.